内容紹介
Summary
Endocrine therapy is effective for elderly patients who are diagnosed with estrogen receptor-positive breast cancer and cannot receive surgical treatment or chemotherapy because of advanced age. The duration of response in patients receiving letrozole is approximately 10.3 months. There are few cases with more than 3 years of response. We evaluated the significance of indoleamine 2,3-dioxygenase(IDO)during letrozole therapy in long-term response. We measured IDO activity based on the tryptophan(Trp)/kynurenine(Kyn)ratio. Trp and Kyn levels were measured using high-performance liquid chromatography(HPLC). The Trp/Kyn ratio decreased along with tumor reduction after letrozole therapy. These results suggest that measuring the Trp/Kyn ratio may be useful for evaluating immunological status during endocrine therapy in elderly patients with locally advanced breast cancer.
要旨
letrozoleは高齢者の内分泌受容体陽性乳癌に対して有効であるが,平均奏効期間は10.3か月程度とされており,3年以上奏効した報告は少ない。letrozoleが長期間奏効した内分泌受容体陽性の高齢者乳癌症例に対して,その治療経過をインドールアミン酸素添加酵素(indoleamine 2,3-dioxygenase: IDO)の発現から検索した。
目次
Endocrine therapy is effective for elderly patients who are diagnosed with estrogen receptor-positive breast cancer and cannot receive surgical treatment or chemotherapy because of advanced age. The duration of response in patients receiving letrozole is approximately 10.3 months. There are few cases with more than 3 years of response. We evaluated the significance of indoleamine 2,3-dioxygenase(IDO)during letrozole therapy in long-term response. We measured IDO activity based on the tryptophan(Trp)/kynurenine(Kyn)ratio. Trp and Kyn levels were measured using high-performance liquid chromatography(HPLC). The Trp/Kyn ratio decreased along with tumor reduction after letrozole therapy. These results suggest that measuring the Trp/Kyn ratio may be useful for evaluating immunological status during endocrine therapy in elderly patients with locally advanced breast cancer.
要旨
letrozoleは高齢者の内分泌受容体陽性乳癌に対して有効であるが,平均奏効期間は10.3か月程度とされており,3年以上奏効した報告は少ない。letrozoleが長期間奏効した内分泌受容体陽性の高齢者乳癌症例に対して,その治療経過をインドールアミン酸素添加酵素(indoleamine 2,3-dioxygenase: IDO)の発現から検索した。